Senior Director
Evonik
BIRMINGHAM, Alabama
Thomas R. Tice, PhD, Senior Director, Global Startegic and Technical Marketing, Evonik Corporation, provides scientific support to Evonik’s product development, sales, M&A, and intellectual property teams. Dr. Tice is internationally recognized for research in drug delivery and has lectured on the topic throughout the world. His specialties include complex parenteral dosage forms and bioabsorbable polymers. He has over 40 years’ experience developing injectable, extended-release microparticles and implants made with bioabsorbable lactide/glycolide polymers. He led the team and is one of the inventors that developed the first commercial, injectable, extended-release microparticle product. This product is Decapeptyl® SR, a one-month LHRH formulation indicated for the treatment of prostate cancer. Dr. Tice earned his PhD in Biophysics from Syracuse University, New York. He holds 48 US patents with many foreign equivalents and has more than 180 publications, presentations and invited lectures to his credit. He currently serves on the Board of McWhorter School of Pharmacy at Samford University and serves on two United States Pharmacopeia expert committees - the General Chapters-Dosage Forms Expert Committee and the Nomenclature and Labeling Expert Committee.
Disclosure information not submitted.
Tuesday, October 18, 2022
2:00 PM – 3:00 PM ET